Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hailun (also known as Hailun Capsule) is a traditional Mongolian medicine (TMM) developed by the Mongolian Medicine College of Inner Mongolia University for Nationalities. It is formulated as an oral capsule intended for the treatment of patients in the early recovery stage of ischemic stroke, specifically those presenting with blood stasis blocking collaterals syndrome. In traditional Mongolian medicine theory, the preparation is designed to promote blood circulation, resolve blood stasis, and clear the meridians and collaterals to facilitate neurological recovery. It has been evaluated in Phase II clinical trials in China to assess its safety and efficacy in improving functional outcomes following a stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hailun (Inner Mongolia University for Nationalities).